LGALS3 and prostate cancer: The studies presented earlier have shown that intracellular Gal-3 imparts resistance to apoptosis in breast, bladder and prostate cancer cells [27, 28], whereas recombinant Gal-3 is also exogenously added and enhances cancer progression [29].